Compare CDMOs with ISO 14001 environmental management certification. Filter by manufacturing type and sustainability initiatives.
3 companies listed
ISO 14001 is the international standard for environmental management systems (EMS). Pharmaceutical CDMOs with ISO 14001 certification have implemented systematic approaches to managing their environmental impact: waste reduction, energy efficiency, water conservation, solvent recovery, and emissions control. This is increasingly important as pharma companies incorporate sustainability into supplier selection criteria.
Chemical and biological manufacturing processes generate significant environmental footprints. API synthesis uses organic solvents (some classified as hazardous), generates chemical waste, and consumes substantial energy and water. CDMOs with ISO 14001 certification demonstrate they are actively managing these impacts through measurement, targets, and continuous improvement programs.
INDIA
INA Pharmaceuticals is an India-based pharmaceutical manufacturing and CDMO company specializing in pharmaceutical intermediates, advanced intermediates and custom synthesis solutions for global pharmaceutical partners. We support customers from route development and process optimization through scale-up and commercial manufacturing, with a focus on consistent quality, reliable supply and long-term partnerships. Our capabilities include: - Pharmaceutical intermediates and advanced intermediates - Custom synthesis and contract manufacturing - Process development and optimization - Route scouting and scale-up - Commercial-scale manufacturing - Technology transfer - Impurity and related-substance synthesis - Customized manufacturing solutions based on customer requirements We work with pharmaceutical companies, generic manufacturers, CDMOs, CROs and sourcing organizations seeking reliable manufacturing partners in India. We are actively looking for: - Long-term supply partnerships - Custom synthesis projects - CDMO collaborations - Technology-transfer opportunities - Joint development projects - Strategic partnerships with overseas pharmaceutical companies Our objective: to become a reliable long-term manufacturing partner for pharmaceutical companies seeking high-quality intermediates and flexible CDMO solutions from India.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
China
Chengda Pharmaceutical positions itself as a CDMO partner with over two decades of experience, focusing on process development and industrialization for key pharmaceutical intermediates and APIs. Its core strengths lie in a combination of regulatory compliance, flexible production capabilities, and strategic expansion into high-growth therapeutic areas. Regulatory Compliance and Global Market Access Chengda has established a robust quality management system that integrates drug cGMP (ICH Q7) with ISO9001 and other standards, enabling it to meet the stringent requirements of multinational pharmaceutical companies. The company has successfully passed on-site inspections by regulatory agencies including the U.S. FDA, China's NMPA, Japan's PMDA, and Malaysia's NPRA. Its API registration applications have also passed technical reviews by authorities such as the FDA, EDQM, and Health Canada. This compliance infrastructure allows Chengda to embed its CDMO services directly into the innovation chains of its clients, supporting both clinical development and commercial manufacturing. Production Flexibility and End-to-End Service Capability The company offers a broad service range spanning from kilogram to ton-scale production of key intermediates and APIs, covering process R&D, optimization, analytical method development and validation, stability studies, and customized manufacturing. Its production facilities are designed for diverse chemical reactions, featuring capabilities for ultra-low temperature reactions (down to -78°C), high-pressure hydrogenation, anhydrous and oxygen-free synthesis, and chiral compound synthesis. With a total reaction volume of approximately 950,000 liters and multiple clean rooms, Chengda can accommodate different scales and technical requirements, from preclinical studies to commercial launch. Strategic Positioning in High-Growth Modalities Chengda has made strategic moves into two high-growth areas: small-molecule GLP-1 intermediates for weight management and oligonucleotide (small nucleic acid) intermediates. The company has progressed from laboratory development to commercial-scale readiness for GLP-1 intermediates and can supply high-quality monomers and delivery system intermediates for siRNA and ASO drugs. This expansion leverages its existing expertise in complex chemical synthesis and positions the company to capture demand in these rapidly expanding therapeutic categories. Proven Track Record with Global Clients Chengda's client base includes multinational pharmaceutical companies such as Incyte, Helsinn, Eli Lilly/Evonik, Gilead, and GSK. Its ability to maintain long-term relationships and expand the scope of collaboration reflects a consistent delivery record and growing client trust in its technical and manufacturing capabilities